The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
An International Randomised Trial Of Low-dose Aspirin To Prevent Recurrent Venous Thromboembolism (INSPIRE)
Funder
National Health and Medical Research Council
Funding Amount
$1,989,986.00
Summary
Patients who develop venous blood clots or pulmonary embolism, without an underyling cause, are at very high risk of recurrence once anticoagulant treatment (warfarin) is discontinued. The international INSPIRE trial is assessing whether low-dose aspirin treatment (a simple and cheap alternative to warfarin) is effective and safe in preventing further blood clots. If proven effective, aspirin could potentially prevent thousands of patients worldwide from experiencing such events.
Low-dose Aspirin To Prevent Recurrent Venous Thromboembolism (ASPIRE) Study: A Multicentre Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,108,600.00
Summary
In approximately one-third of patients who develop deep vein thrombosis or pulmonary embolism, this event is 'unprovoked' . These patients are at very high risk of recurrence once treatment with warfarin is discontinued. Warfarin treatment is very effective to prevent recurrence but is inconvenient because it has to be very closely monitored with blood tests and also causes serious bleeding complications in a significant number of patients. There are currently no other treatments available to pr ....In approximately one-third of patients who develop deep vein thrombosis or pulmonary embolism, this event is 'unprovoked' . These patients are at very high risk of recurrence once treatment with warfarin is discontinued. Warfarin treatment is very effective to prevent recurrence but is inconvenient because it has to be very closely monitored with blood tests and also causes serious bleeding complications in a significant number of patients. There are currently no other treatments available to prevent recurrent thrombosis. Low-dose aspirin treatment offers a simple, inexpensive, and widely practicable alternative to warfarin but has not yet been proven to be effective for preventing recurrent thrombosis. This study will investigate the effectiveness and safety of aspirin to prevent recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism who have completed standard anticoagulation with heparin and warfarin. If proven to be effective, aspirin could potentially prevent thousands of patients from experiencing recurrent venous thromboembolism or fatal pulmonary embolism worldwide and also save millions of dollars in health care costs each year.Read moreRead less
Centre For Training In Clinical Cardiovascular And Cerebrovascular Research
Funder
National Health and Medical Research Council
Funding Amount
$2,000,000.00
Summary
This Centre proposes to expand its highly successful Centre of Clinical Excellence funded by NHMRC from 1998-2001. The Centre provided the opportunity in Western Australia for the highest quality clinical research training in comprehensive spheres relevant to the pathogenesis, prevention and therapeutics of cardiovascular disease, with an emphasis on the role of nutrition and lifestyle in relation to high blood pressure, arteriosclerosis, dyslipidaemia and the function of blood vessels. The new ....This Centre proposes to expand its highly successful Centre of Clinical Excellence funded by NHMRC from 1998-2001. The Centre provided the opportunity in Western Australia for the highest quality clinical research training in comprehensive spheres relevant to the pathogenesis, prevention and therapeutics of cardiovascular disease, with an emphasis on the role of nutrition and lifestyle in relation to high blood pressure, arteriosclerosis, dyslipidaemia and the function of blood vessels. The new Centre will broaden the scope of its research and training activities, through the inclusion of clinical projects related to heart failure, clinical and epidemiological research into cerebrovascular disease and stroke and research training opportunities with respect to clotting disorders and therapeutics for thrombosis.Read moreRead less
Monomeric C-reactive Protein As Pathogenic Factor And Therapeutic Target In Athero-thrombotic Disease.
Funder
National Health and Medical Research Council
Funding Amount
$86,570.00
Summary
Vascular disease of the heart, brain and limbs affects many people in Australia and throughout the world. Current treatments assist in slowing the development and progression of established disease, but new developments are required. This project will investigate the role of C-reactive protein in vascular disease and evaluate its potential as a new therapeutic target in the future.
Platelet-Activating And Proinflammatory Effects Of Proteins Secreted By Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$515,986.00
Summary
Skin or other Staphylococcus aureus (SA, golden Staph.) infections are common in Aboriginal Australians. We address the question whether atherosclerotic disease is accelerated by this bacterial infection. We will investigate whether a class of newly described toxins secreted by SA activates blood cells and leads to clot formation and potentially heart attack. We will evaluate plasma samples from cardiac patients and Aboriginal Austr. and will develop and test therapeutics in vitro and in mice.